[Hengrui Medicine: Subsidiary HRS-5346 tablets are approved to carry out Phase III clinical trials] On November 9, Hengrui Medicine (600276.SH) announced that the company's subsidiary Shandong Shengdi Medicine has received the approval and issuance of the "Drug Clinical Trial Approval Notice" for HRS-5346 tablets from the State Food and Drug Administration, agreeing to carry out Phase III clinical trials of this product. The drug is an oral small molecule inhibitor of Lp(a), used to reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease or an increased risk of first cardiovascular event who are associated with elevated lipoprotein(a). At present, no similar drugs at home and abroad have been approved for marketing, and the cumulative R&D investment in related projects is approximately 86.2 million yuan.